PROFIL-1: Inclusion and Exclusion Criteria for NSCLC Chemo-Immunotherapy PET Study

A prospective single-arm biomarker pilot study investigating the prognostic and predictive potential of multiparametric 18F-FDG LAFOV-PET for first-line chemo-immunotherapy efficacy in advanced non-small-cell lung cancer. The study, authored by Margaux Geier, opened for enrolment in January 2025 and plans to include 120 patients at 2 French sites over a 2-year inclusion period. The dataset contains the study's inclusion and exclusion criteria.

Use Cases

• Identifying eligible patient cohorts for clinical trials based on the specified inclusion and exclusion criteria.
• Analyzing the relationship between imaging parameters and clinical outcomes, as referenced in the study's secondary endpoints.
• Comparing reconstruction methods for dynamic PET parameters like Ki and distribution volume, as mentioned in the study description.
• Assessing the prognostic potential of radiomic features derived from LAFOV-PET scans for chemo-immunotherapy response.

Strengths

• Data is associated with a registered clinical trial (NCT06738680) with a defined protocol.
• Study has a clear, prospective design with a planned enrolment of 120 patients.
• Dataset is openly licensed under CC-BY-4.0.

Limitations

• Row count and column-level documentation are unknown; field semantics must be inferred after download.
• The dataset is very small (9.5 KB), indicating it likely contains only metadata or criteria lists, not the full clinical or imaging data.
• Data may reflect geographic bias inherent to its collection from 2 French sites.

Provenance

Source

figshare, authored by Margaux Geier.

Collection Method

Prospective clinical trial data collection.

Time Range

Study opened for enrolment in January 2025, with a planned 2-year inclusion period.

Freshness

Last updated 2026-04-03 17:40:15; freshness should be verified.

Geography

Data collected from 2 French sites.